Evidence map›Paper›PMID 27387204›Full record

ArticleBMC cancer2016

Chemotherapy versus radiotherapy for FIGO stages IB1 and IIA1 cervical carcinoma patients with postoperative isolated deep stromal invasion: a retrospective study.

Lei Li, XiaoYan Song, RuoNan Liu, Nan Li, Ye Zhang, Yan Cheng, HongTu Chao, LiYing Wang

Open access · goldAbstract readComparative Study
In one paragraph

Article in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 4 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 4 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Lei LiDepartment of Gynecologic Oncology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, 450008, China. lilei04301596@163.com.
XiaoYan SongDepartment of Clinical Laboratory, the Third Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
RuoNan LiuDepartment of Gynecologic Oncology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, 450008, China.
Nan LiDepartment of Gynecologic Oncology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, 450008, China.
Ye ZhangDepartment of Gynecologic Oncology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, 450008, China.
Yan ChengDepartment of Gynecologic Oncology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, 450008, China.
HongTu ChaoDepartment of Gynecologic Oncology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, 450008, China.
LiYing WangDepartment of Gynecologic Oncology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, 450008, China.
Zhengzhou University · CNThird Affiliated Hospital of Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe adjuvant treatment for patients with isolated stromal invasion after radical hysterectomy and pelvic lymph node dissection (PLND) in FIGO stage IB1 and IIA1 cervical carcinoma has not been established. This study assessed the survival outcomes and recurrent patterns in this particular group of patients treated with chemotherapy or radiation-based adjuvant therapy.

methodsThe records 133 IB1 and IIA1 postoperative cervical carcinoma patients with histopathology-confirmed isolated deep stromal invasion (DSI) without any other unfavorable pathological finding between June 2010 and March 2013 were analyzed. Sixty-five patients received postoperative adjuvant four to six cycles of cisplatin-based chemotherapy (CT group) and Sixty-eight received postoperative received postoperative adjuvant radiotherapy (RT group). Treatment-related toxicities were evaluated and disease-free survival (DFS) and overall survival (OS) were analyzed using Kaplan-Meier estimates and statistical significance was determined using the log-rank test.

resultsWith a median follow-up of 33.7 months (range 10-62 months), RT group had a significantly improved in DFS rate (P = 0.044), but there was no significant difference in overall survival (P = 0.437). Upon further analysis, patients with outer 1/3 to full-thickness invasion in chemotherapy group exhibited significantly higher recurrence rates compared to the radiotherapy group. Leukocytopenia, nausea and vomiting were the most frequent short-term complications of chemotherapy, whereas colitis/proctitis and cystitis were more frequent in the radiotherapy group (P = 0.000 respectively). No significant differences were found regards to other acute toxicities, including hemoglobin, platelets and ALT/AST, colitis/proctitis, cystitis and dermatitis (P = 0.000 respectively). Fewer late severe side effects in the chemotherapy group were observed compared with the radiation group and significant differences were found at colitis/proctitis, cystitis and dermatitis (P = 0.000 respectively).

conclusionCompared to chemotherapy alone, postoperative RT to FIGO stages IB1 and IIA1 cervical carcinoma patients with isolated DSI can reduce risk of recurrence and with acceptable morbidity.

Indexed as

AdultAgedChemotherapy, AdjuvantCisplatinFemaleHumansHysterectomyMiddle AgedNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingRadiotherapy, AdjuvantRetrospective StudiesSurvival AnalysisTreatment OutcomeUterine Cervical NeoplasmsCisplatinCervical cancerChemotherapyDeep stromal invasion (DSI)Radiotherapy

Identifiers

PMID27387204
PMCPMC4936260
OpenAlexW2470916285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.